Abstract
Background: Anemia is an important public health and clinical problem. Observational studies have linked iron deficiency and anemia in children with many poor outcomes, including impaired cognitive development; however, iron supplementation, a widely used preventive and therapeutic strategy, is associated with adverse effects. Primary-school–aged children are at a critical stage in intellectual development, and optimization of their cognitive performance could have long-lasting individual and population benefits. In this study, we summarize the evidence for the benefits and safety of daily iron supplementation in primary-school–aged children.
Methods: We searched electronic databases (including MEDLINE and Embase) and other sources (July 2013) for randomized and quasi-randomized controlled trials involving daily iron supplementation in children aged 5–12 years. We combined the data using random effects meta-analysis.
Results: We identified 16 501 studies; of these, we evaluated 76 full-text papers and included 32 studies including 7089 children. Of the included studies, 31 were conducted in low- or middle-income settings. Iron supplementation improved global cognitive scores (standardized mean difference 0.50, 95% confidence interval [CI] 0.11 to 0.90, p = 0.01), intelligence quotient among anemic children (mean difference 4.55, 95% CI 0.16 to 8.94, p = 0.04) and measures of attention and concentration. Iron supplementation also improved age-adjusted height among all children and age-adjusted weight among anemic children. Iron supplementation reduced the risk of anemia by 50% and the risk of iron deficiency by 79%. Adherence in the trial settings was generally high. Safety data were limited.
Interpretation: Our analysis suggests that iron supplementation safely improves hematologic and nonhematologic outcomes among primary-school–aged children in low- or middle-income settings and is well-tolerated.
See related commentary by Gray-Donald at www.cmaj.ca/lookup/doi/10.1503/cmaj.131249
An estimated 25% of school-aged children worldwide are anemic.1 Iron deficiency is thought to account for about half of the global cases of anemia2 and is associated with inadequate dietary iron and, in developing settings, hookworm and schistosomiasis.3 In developed settings, anemia is prevalent among disadvantaged populations, including newly arrived refugees, indigenous people4 and some ethnic groups (e.g., Hispanic people in the United States).5,6 About 3% of primary-school–aged children in Canada are anemic.7 Programs to address anemia are constrained by concerns that iron supplements cause adverse effects, including an increased risk of infections such as malaria in endemic areas.8
In observational studies, iron deficiency has been associated with impaired cognitive and physical development. It has been estimated that each 10 g/L decrement in hemoglobin reduces future intelligence quotient (IQ) by 1.73 points.9 However, observational data are susceptible to confounding,10 and a causal relation between iron deficiency and cognitive impairment has not been confirmed.11 Randomized controlled trials should overcome confounding, but results of trials examining this question have not agreed.
Optimizing cognitive and physical development in primary-school–aged children could have life-long benefits.12 However, anemia-control recommendations must balance safety and efficacy. We performed a systematic review of the effects of daily iron supplementation, a commonly used strategy to combat anemia,2 in primary-school–aged children. We examined cognitive, growth and hematologic outcomes and adverse effects across all settings.
Methods
The protocol for our systematic review and meta-analysis is registered with PROSPERO (www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42011001208). We included outcomes that could be used to inform guidelines for anemia control.13
Information sources
We searched the following electronic databases: Scopus, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, ProQuest Digital Theses, the Australian Digital Theses Program database, WHO regional databases and Open-Grey. We reviewed the references of the identified articles and of previous systematic reviews. There was no language restriction applied. The search strategy for Scopus is presented in Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.130628/-/DC1). We performed the searches on July 4, 2013, for all databases except Embase (searched in June 2011). We searched the World Health Organization’s International Clinical Trials Registry Platform in July 2013 for potentially eligible ongoing trials.
Inclusion criteria
We included randomized controlled trials that included primary-school–aged children (5–12 yr) who were randomly assigned to daily (≥ 5 d/wk) oral iron supplementation or control. We included studies that did not specifically recruit participants from this age range if the mean or median age of participants was between 5 and 12 years, if more than 75% of participants were aged 5–12 years, or if most of the study’s recruitment age range overlapped 5–12 years. We excluded studies that included only children with a known developmental disability or a condition that substantially altered iron metabolism, including severe anemia. We included trials involving participants from all countries and socioeconomic backgrounds.
Outcomes
We included the following primary outcomes: cognitive performance (as measured by study authors); physical growth; safety (gastrointestinal adverse effects, infection [including malaria], morbidity and, if measured, mortality); and hemoglobin, iron indices, prevalence of anemia (hemoglobin < 120 g/L or as defined by study authors) and iron deficiency.
The secondary outcomes were the effects of iron on other micronutrients (including zinc) and physical performance.
Data extraction
Three authors (M.L., A.F., S.-R.P.) screened the titles and abstracts identified by the search and excluded clearly ineligible references. Two authors (M.L., A.F.) independently assessed the remaining full-text studies against the inclusion criteria; their assessments were checked by a third author (S.-R.P.). Data were independently extracted by 2 authors (M.L, A.F.) and checked by a third author (S.-R.P.). One author (M.L.) entered the data into Review Manager software (RevMan 5.1, The Cochrane Collaboration) and a second author (S.-R.P.) checked entries for accuracy. Discrepancies were resolved through discussion.
Assessment of risk of bias
We assessed the risk of bias by use of the Cochrane risk of bias assessment tool, which addresses selection, performance, attrition, detection and reporting bias through the evaluation of reported sequence generation, allocation concealment, blinding, incomplete outcome data and selective outcome reporting.14 We used sensitivity analysis to examine the effects of removing studies with a high risk of bias (studies with poor or unclear randomization or allocation concealment, and poor or unclear blinding or high or imbalanced losses to follow-up) from the analysis.15 For outcomes that had more than 10 included trials, we examined funnel plots for evidence of publication bias.
Statistical analysis
Meta-analysis was performed for outcomes for which at least 2 studies provided data. We determined the mean difference (MD) for the difference between outcome means or the change from baseline for continuous data measured on the same scale. We calculated standardized mean differences (SMDs; difference of means is standardized according to standard deviation) for continuous data that were reported using different scales. If for a particular outcome, some studies reported outcome data only and others reported change from baseline data only, these data were combined using MD if the same scale had been used. If both outcome and change data were reported in the same study for the same outcome, the outcome data were used. For dichotomous data, the results are presented as risk ratios (RRs). For rates, the results are presented as rate ratios.
We included studies that provided iron supplementation along with a second intervention (cointervention), provided that the cointervention was applied identically in the control arm. For studies with a 2 × 2 factorial design (e.g., participants randomized to iron or control, then a second randomization to another intervention or control), we extracted the data and entered them into the meta-analysis separately.
We quantified heterogeneity using I2. We considered substantial heterogeneity to exist if I2 was above 50%. We performed predefined subgroup analyses for outcomes that had 5 or more included studies. We included the following subgroups: baseline anemia status; baseline iron status; baseline iron deficiency anemia status; dose of iron supplementation; duration of iron supplementation; iron combination (iron alone or with a cointervention); and reported malaria endemicity of the setting. Differences between subgroups were tested using χ2 and I2 statistics.16 We created forest plots to present the effect size and relative weights for each study and the overall calculated effect size. Random-effects meta-analysis was used with calculation of τ2 because of potential statistical, clinical and methodologic heterogeneity.8
Results
The selection of studies for inclusion is illustrated in Figure 1. Our search strategy identified 16 501 potentially eligible titles and abstracts. We did not identify any potentially eligible unpublished trials in the International Clinical Trials Registry Platform. Following screening, 32 studies were deemed eligible; this included 7089 children (3837 randomized to iron supplements and 3252 to control). All studies except 1 were performed in low- or middle-income countries. Table 1 presents the characteristics of the included studies. Only 4 studies were considered at low overall risk of bias (Table 2).
The primary outcome findings are presented in Table 3. A complete table of findings including secondary outcomes is presented in Appendix 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.130628/-/DC1.
Cognition
No studies reporting cognitive outcomes were at low overall risk of bias.
Global cognitive performance
Global cognitive performance was reported in 9 studies: 5 studies used IQ (tests: Raven Progressive Matrices, Wechsler Intelligence Scale for Children [WISC], Test of Non-verbal Intelligence 2nd Edition),28,43,44,55–58 3 studies used author-adapted scales of global cognitive performance (visual memory, digit span, mazes test, clerical task tests with maximum scores of 40),28–31,34 and 1 study used overall school performance.17,18
Data from 2 other studies could not be included because global cognitive scores were not presented. Sen and Kanani52,53 found significant improvements from iron supplementation in digit span, maze testing and visual memory testing but not clerical tasks in 110 girls aged 9–13 years. Rico and colleagues47–50 found no difference with iron supplementation on various cognitive domains measured with an adapted WISC in 590 children aged 6–8 years other than a small significant improvement in responses on the stimulus discrimination task.
Children who received iron supplementation had higher global cognitive scores at the end of the intervention compared with children who received the control (SMD 0.50, 95% confidence interval [CI] 0.11 to 0.90; p = 0.01, I2 = 93%, 9 studies, n = 2355) (Figure 2). This beneficial effect was seen among children who were anemic at baseline (SMD 0.29, 95% CI 0.07 to 0.51; p = 0.01, I2 = 22%, 6 studies, n = 487) but not among those without anemia (SMD 0.01, 95% CI −0.10 to 0.11; p = 0.9, I2 = 0%, 4 studies, n = 1361) (test for subgroup difference: p = 0.05). Although fewer than 10 studies reported this outcome, a Funnel plot did not indicate publication bias (Appendix 3, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.130628/-/DC1).
Intelligence quotient
The most commonly reported global cognitive score was age-adjusted IQ. There was no overall benefit of iron supplementation on IQ scores (MD 5.47, 95% CI −3.24 to 4.18; p = 0.2, I2 = 97%, 5 studies, n = 1874). However, our subgroup analysis showed that children who had anemia at baseline had significant improvements in their IQ after iron supplementation compared with children who received the control (MD 4.55, 95% CI 0.16 to 8.94; p = 0.04, I2 = 28%, 3 studies, n = 186) (Appendix 3).
Other cognitive tests
Compared with children in the control group, children who received iron supplementation had superior performance on the maze test (MD 1.30, 95% CI 0.9 to 1.7; p < 0.001, I2 = 0%, 4 studies, n = 288) and clerical task scores (SMD 0.44, 95% CI 0.14 to 0.75; p = 0.005, I2 = 30%, 4 studies, n = 290). There was no difference between iron supplementation and control for other measures including digit span, visual memory score, math scores and language test scores (Appendix 2).
Growth
Height
Iron supplementation was not associated with a difference in absolute height. However, children who received iron supplements experienced a small advantage in height-for-age (z score) (Figure 3). When we included only studies with a low risk of bias, the benefit of iron supplementation was still apparent (MD 0.12, 95% CI 0.00 to 0.23; p = 0.05, 2 studies, n = 922).
Weight
There was no difference in absolute weight or weight-for-age (z score) between children who received iron or control. One study included subgroups of children with iron deficiency anemia and children without iron deficiency or anemia.24 The authors reported that the children with iron deficiency anemia who received iron had a significant improvement in weight-for-age (MD 0.13, 95% CI 0.04 to 0.22; p = 0.005, n = 78); this effect was not seen among children without anemia (MD 0.18, 95% CI −0.24 to 0.60; p = 0.4, n = 57).24
Safety
Malaria infection
The prevalence of malaria parasitemia was similar between iron and control groups (RR 1.10, 95% CI 0.94 to 1.29; p = 0.9, I2 = 93%, 4 studies, n = 919) (Appendix 4, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.130628/-/DC1). There were no differences in the rate of positive tests for all malaria infections (rate ratio 1.05, 95% CI 0.90 to 1.21; p = 0.6, I2 = 0%, 4 studies, n = 1818), Plasmodium falciparum infections (rate ratio 1.02, 95% CI 0.81 to 1.29; p = 0.9, I2 = 0%, 2 studies, n = 1136) and Plasmodium vivax infections (rate ratio 1.07, 95% CI 0.85 to 1.34; p = 0.6, I2 = 0%, 2 studies, n = 1136).
Other infections
De Silva and colleagues25 reported fewer respiratory tract infections (MD −0.56, 95% CI −0.82 to −0.30; p < 0.001, n = 363) and fewer days off sick with respiratory tract infections (MD −7.04, 95% CI −9.75 to −4.33; p < 0.001, n = 363) among children who received iron supplementation. Richard and colleagues46 reported no difference in the rate of acute respiratory tract infections between groups (rate ratio 0.91, 95% CI 0.65–1.27; p = 0.6, n = 836).
Gastrointestinal adverse effects
There was no difference in the number of children with gastrointestinal upset, constipation, vomiting or diarrhea or the rates of diarrhea between children who received iron supplementation or control (Appendix 4).
Morbidity and mortality
Chwang and colleagues24 reported that children who received iron supplementation had a lower overall morbidity score than children in the control group (MD −2.73, 95% CI −3.56 to −1.90; p < 0.001, n = 119). Mortality, admission to hospital, nonregular clinic visits and morbidity from iron poisoning were not reported in any study.
Hematologic and iron indices
Iron supplementation improved hemoglobin and ferritin levels, anemia and iron deficiency (Table 3, Appendix 2, Appendix 5 [available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.130628/-/DC1]). Funnel plots for hemoglobin and ferritin levels did not show any evidence of publication bias (Appendix 5). When we included only the 4 studies at low risk of bias, the beneficial effects of iron supplementation were no longer observed for hemoglobin, ferritin or iron deficiency.
Only 2 studies reported iron deficiency anemia.17,18,57,58 Iron supplementation reduced the prevalence of anemia (RR 0.12, 95% CI 0.02 to 0.66; p = 0.01, 334 children).
Other micronutrients
There were no differences in the prevalence of zinc deficiency51 or in the serum levels of zinc,51 lead,47–50 retinol26 or copper.42
Exercise performance
Gopaldas and colleagues28–31 reported a reduction in pulse rate during the Harvard Step Test among children who received iron supplementation. However, Sen and Kanani52,53 found no difference between the iron and control groups in the number of steps climbed or recovery time.
Adherence
Twenty-one studies reported adherence. We were unable, however, to perform a meta-analysis because of differences in reporting. Five studies (835 children) used fully or partially supervised iron supplementation. Of the remaining studies, 4 (820 children) reported adherence of more than 90% in the control and iron supplementation groups,21,25,27,57,58 and 7 studies (2071 children) reported more than 80% compliance in both groups.19,21,25,27,33,46,57,58 Only 3 studies reported lower adherence rates: Sen and Kanani52–54 reported an adherence rate of 72%, and Nchito and colleagues38–40 adherence of 50%. Six studies (2651 children) excluded participants who failed to take a predefined percentage of supplements (ranging from 66% to 90% of total tablets).22,23,44,47–51,55 Five studies (1894 children) compared adherence between children taking iron and control; they reported similar proportions of children taking at least a specified percentage of tablets.19,21,25,27,33
Interpretation
Daily supplementation provides the highest dose of iron of any nonparenteral approach and is a commonly recommended clinical and public health strategy for the prevention and treatment of anemia.2 Potential strategies for anemia control include improved dietary iron by improving dietary diversity or fortification of staple foods and condiments, home-based fortification with multiple micronutrients, iron supplementation and control of helminthic infection.6 Our data are chiefly extrapolatable to iron supplementation interventions; alternative approaches to improving iron stores such as food fortification are under evaluation by other systematic reviews.61
In this review, we found evidence of a benefit of iron supplementation on cognitive performance among primary-school–aged children, including on IQ among children with anemia. Iron may also improve growth. Daily iron supplementation decreased the prevalence of anemia by about 50% and reduced the prevalence of iron deficiency by 79%. Iron supplements appear to be well-tolerated, but safety data are limited.
Previous systematic reviews have evaluated the efficacy of iron delivered by multiple approaches (i.e., supplementation, parenteral administration, fortification) among children of broad age ranges; outcomes included hemoglobin level,62 mental and physical development,63 growth,64 exercise capacity,65 malaria8 and infectious diseases66 (but not other adverse effects). Iron supplementation among iron-deficient children without anemia has also been reviewed.67 A Cochrane review of intermittent iron supplementation in children found insufficient studies reporting cognitive outcomes or adverse effects.15
Two previous reviews have evaluated the effects of iron on cognitive outcomes among primary-school–aged children. Sachdev and colleagues63 reported improvements in overall cognitive performance (SMD 0.30) and IQ (SMD 0.41) among children who received parenteral or enteral iron (including fortification). Falkingham and colleagues68 found no improvement in overall IQ from iron supplementation, but they reported improvements in IQ among participants with anemia (MD 2.5) and improvements in attention and concentration among adults and children older than 6 years of age.
Our search strategy enabled us to identify and include more eligible studies than either Falkingham and colleagues68 (5 additional studies) or Sachdev and colleagues63 (7 additional studies). We have improved on previous reviews by performing a broader search, providing a comprehensive evaluation of the benefits and safety, and addressing a specific, widely used strategy of iron administration among children at an age at which developmental benefits are critical.
Limitations
Our conclusions are limited by poor reporting in the included studies: many studies did not report the randomization method (20 studies), allocation concealment (25 studies) or blinding (18 studies). Although biochemically measured outcomes (e.g., hematologic and iron indices) are unlikely to be affected by the blinding of outcome assessors, cognitive scores have the potential for performance and detection bias.
Our review is also limited by significant heterogeneity, which we addressed by use of random effects meta-analysis and predefined subgroup analyses. This heterogeneity appears to be mainly because of differences in baseline anemia status. Unfortunately, several important outcomes (particularly physical performance and growth) were reported by relatively few studies, and only 6 studies reported safety outcomes. Further randomized trials evaluating the nonhematologic effects of iron, especially outcomes such as cognitive performance, growth and safety, are needed.
Conclusion
In this review, we found evidence that iron supplementation benefits global cognitive performance. Anemia and iron deficiency were prevalent in the included studies (69% and 59%, respectively, in the control groups); thus, routine daily iron supplementation is likely to benefit cognitive performance in primary-school–aged children in developing settings where anemia is prevalent and testing hemoglobin before iron supplementation may not be feasible. In developed settings, our data support ensuring that anemia is detected and treated. Reductions in the prevalence of anemia and iron deficiency reported here should guide the targets of anemia-control programs. Cognitive performance is associated with educational achievement,69 future income and productivity.70 Daily iron supplementation could benefit educational attainment and economic potential at the individual level and, in settings where anemia is prevalent, population level.
Acknowledgements:
The authors thank the staff in the Department of Nutrition for Health and Development and the Library and Information Networks for Knowledge, World Health Organization, Geneva, for their guidance and assistance in planning and implementing this study. They also thank Patrick Condron, librarian at The University of Melbourne, for assistance with the electronic search strategies, and Maggie Low, University of Adelaide, and Dr. Denise Lee, Alfred Hospital, for assistance with acquiring the publications.
Footnotes
Competing interests: Michael Low has received travel expenses from Gilead Sciences. Sant-Rayn Pasricha is co-investigator on an unrestricted research grant from Vifor Pharma. No competing interests declared by Ann Farrell and Beverly-Ann Biggs.
This article has been peer reviewed.
Contributors: Sant-Rayn Pasricha and Michael Low conceived the systematic review design, developed the search strategy, undertook the search, screened papers for eligibility, extracted data, analyzed the results and wrote the manuscript. Ann Farrell screened papers for eligibility, extracted data and wrote the manuscript. Beverley-Ann Biggs conceived the systematic review design, interpreted the data and revised the manuscript critically for important intellectual content. All of the authors approved the final version submitted for publication.
Funding: Sant-Rayn Pasricha was supported by a Victoria Fellowship from the Government of Victoria; a CRB Black-burn Scholarship from the Royal Australasian College of Physicians; an Overseas Research Experience Scholarship from the University of Melbourne; and a National Health and Medical Research Council CJ Martin Early Career Fellowship. Michael Low was supported by an Alfred Research Trust Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.